Sai Life Sciences IPO Details, Financials, Valuation & Peers
Explore Sai Life Sciences IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Sai Life Sciences Limited is a innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO) catering to global pharmaceutical and biotechnology companies. Specializing in small molecule New Chemical Entities (NCE), the company offers comprehensive services spanning the drug discovery, development, and manufacturing value chain. Sai Life Sciences operates through a hybrid delivery model, with research laboratories near innovation hubs in the United States and the United Kingdom, complemented by cost-competitive large-scale facilities in India. Sai Life Sciences has served over 280 pharmaceutical innovators, including 18 of the top 25 global pharmaceutical companies in FY2024. The company’s differentiated model combines Discovery/Contract Research (CRO) and Chemistry, Manufacturing, and Control/Contract Development and Manufacturing Organization (CMC/CDMO) services, driving accelerated drug development and commercialization for its clients.
Key Points:
- Comprehensive CRDMO Capabilities
- Discovery Services (CRO): Expertise in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK), having supported over 200 small molecule discovery programs in the last five years.
- Enabled Investigational New Drug (IND) filings for at least 40 programs.
- Contributed to the approval of five drugs now commercially available.
- CDMO Services: Development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for clinical and commercial supplies.
- Portfolio includes 170 innovator pharmaceutical products, with 38 supplied for 28 commercial drugs, including 7 blockbusters.
- Focus on commercial and late-phase products, offering stable revenue streams.
- Discovery Services (CRO): Expertise in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK), having supported over 200 small molecule discovery programs in the last five years.
- Global Presence and Hybrid Delivery Model
- Research laboratories in Watertown, USA, and Manchester, UK, strategically located near innovation hubs.
- Cost-effective manufacturing and research facilities in Hyderabad and Bidar, India.
- Diverse Customer Base
- Served over 280 pharmaceutical companies in FY2024, with no single customer contributing more than 8% of revenue.
- Strong presence in regulated markets, including the US, UK, Europe, and Japan.
- Operational Excellence
- State-of-the-art manufacturing facilities with over 100 customer audits in the past three years.
- Accredited by USFDA, PMDA (Japan), and CDSCO (India), among other regulatory bodies.
- Strong Scientific Expertise: Over 2,350 scientific staff, including 302 PhDs, delivering cutting-edge research and development capabilities.
- Sustainability and ESG Commitment
- Implemented energy-efficient systems, increasing renewable energy usage to 89% at its Bidar facility in FY2024.
- Member of the Pharmaceutical Supply Chain Initiative (PSCI) and rated silver for sustainability by EcoVadis.
Objects of the Issue
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company
- General corporate purposes.
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 11 Dec - 13 Dec 2024 |
| IPO Price Band | ₹522 - ₹549 per share |
| Fresh Issue | ₹950 crore |
| Offer For Sale | 38,116,934 shares (₹2,092.62 crore) |
| Total IPO Size | ₹3,042.62 crore |
| Face Value | ₹1 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 11 Dec 2024 |
| IPO Closing Date | 13 Dec 2024 |
| Basis Of Allotment | 16 Dec 2024 |
| Refunds | 17 Dec 2024 |
| Demat Transfer | 17 Dec 2024 |
| IPO Listing Date | 18 Dec 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Sep 2024 |
|---|---|---|---|---|
| Total Income | 897.74 | 1,245.11 | 1,494.27 | 693.35 |
| Total Expenses | 888.05 | 1,228.70 | 1,385.04 | 656.09 |
| Net Profit/Loss | 6.23 | 9.99 | 82.81 | 28.01 |
| NPM (*) | 0.72 | 0.82 | 5.65 | 4.15 |
| Total Assets | 2,164.23 | 2,186.65 | 2,275.14 | 2,476.78 |
| Total Liabilities | 1,285.67 | 1,298.56 | 1,299.99 | 1,431.22 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Sep 2024 |
|---|---|---|---|---|
| EPS | 0.34 | 0.55 | 4.53 | 1.49 |
| ROE (%) | 0.71 | 1.12 | 8.49 | 2.68 |
| ROCE (%) | 3.21 | 5.13 | 10.26 | 3.90 |
| D/E Ratio | 0.84 | 0.80 | 0.75 | 0.73 |
| Current Ratio | 1.32 | 1.27 | 1.28 | 1.22 |
| EBITDA MARGIN (%) | 15.07 | 14.97 | 20.48 | 20.66 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Sai Life Sciences Limited | 1,465.18 | 121.19 | 4.53 | 8.50 | 53.83 |
| Divi's Laboratories Limited | 7,845.00 | 103.04 | 60.27 | 11.79 | 511.21 |
| Suven Pharmaceuticals Limited | 1,051.35 | 109.37 | 11.80 | 14.64 | 94.04 |
| Syngene International Limited | 3,488.60 | 73.59 | 12.69 | 11.98 | 105.91 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not less than 50% |
| Non-Institutional Investor (NII/HNI) | Not less than 15% |
| Retail Individual Investor (RII) | Not less than 35% |
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 29.78 |
| Non-Institutional Investor (NII/HNI) | 4.99 |
| Retail Individual Investor (RII) | 1.39 |
| Total | 10.27 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
KFin Technologies Limited
Phone: +91 40 6716 2222/ 18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com
Company Promoters
- KANUMURI RANGA RAJU
- KRISHNAM RAJU KANUMURI
- KANUMURI MYTREYI
- SAI QUEST SYN PRIVATE LIMITED
- MARIGOLD PARTNERS
- SUNFLOWER PARTNERS
- TULIP PARTNERS
- LILY PARTNERS
Lead Managers
- Kotak Mahindra Capital Company Limited
- IIFL Capital Services Limited (Formerly known as IIFL Securities Limited)
- Jefferies India Private Limited
- Morgan Stanley India Company Private Limited
Company Address
Sai Life Sciences Limited
Plot No. DS- 7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal – Malkajgiri District, Hyderabad 500 078, Telangana, India
Phone: +91 40 6815 6000
Email: investors@sailife.com
Website: www.sailife.com
FAQs
- What is the issue size of the Sai Life Sciences IPO?The Sai Life Sciences IPO has an issue size of ₹3,042.62 crore. This includes a fresh issue of ₹950 crore and an offer for sale (OFS) of 38,116,934 shares (₹2,092.62 crore).
- What is the price band of the Sai Life Sciences IPO?The price band for the Sai Life Sciences IPO is ₹522 - ₹549 per share.
- What are the bidding dates for the Sai Life Sciences IPO?The Sai Life Sciences IPO will open for bidding on 11 Dec 2024 and close on 13 Dec 2024.
- What is the allotment date for the Sai Life Sciences IPO?The allotment date for the Sai Life Sciences IPO is 16 Dec 2024.
- What is the minimum lot size and investment required for the Sai Life Sciences IPO?The minimum lot size for the Sai Life Sciences IPO is 27 shares and the minimum investment required is ₹14,823.
- What is the listing date for the Sai Life Sciences IPO?The listing date for the Sai Life Sciences IPO is 18 Dec 2024.
- What is the Sai Life Sciences IPO grey market premium?The grey market premium (GMP) for the Sai Life Sciences IPO is currently at ₹72, with an expected listing gain of approximately 13.11%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.